Impact of the β-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between β adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: We evaluated the association between coding region variants of adrenergic receptor genes and therapeutic effect in patients with congestive heart failure (CHF). Methods: One hundred patients with stable CHF (left ventricular ejection fraction [LVEF] < 45%) were enrolled. Enrolled patients started 1.25 mg bisoprolol treatment once daily, then up-titrated to the maximally tolerable dose, at which they were treated for 1 year. Results: Genotypic analysis was carried out, but the results were blinded to the investigators throughout the study period. At position 389 of the β-1 adrenergic receptor gene (ADRB1), the observed minor Gly allele frequency (Gly389Arg + Gly389Gly) was 0.21, and no deviation from Hardy-Weinberg equilibrium was observed in the genotypic distribution of Arg389Gly (p = 0.75). Heart rate was reduced from 80.8 ± 14.3 to 70.0 ± 15.0 beats per minute (p < 0.0001). There was no significant difference in final heart rate across genotypes. However, the Arg389Arg genotype group required significantly more bisoprolol compared to the Gly389X (Gly389Arg + Gly389Gly) group (5.26 ± 2.62 mg vs. 3.96 ± 2.05 mg, p = 0.022). There were no significant differences in LVEF changes or remodeling between two groups. Also, changes in exercise capacity and brain natriuretic peptide level were not significant. However, interestingly, there was a two-fold higher rate of readmission (21.2% vs. 10.0%, p = 0.162) and one CHF-related death in the Arg389Arg group. Conclusions: The ADRB1 Gly389X genotype showed greater response to bisoprolol than the Arg389Arg genotype, suggesting the potential of individually tailoring β-blocker therapy according to genotype.
Abstract
Background/Aims: We evaluated the association between coding region variants of adrenergic receptor genes and therapeutic effect in patients with congestive heart failure (CHF). Methods: One hundred patients with stable CHF (left ventricular ejection fraction [LVEF] < 45%) were enrolled. Enrolled patients started 1.25 mg bisoprolol treatment once daily, then up-titrated to the maximally tolerable dose, at which they were treated for 1 year. Results: Genotypic analysis was carried out, but the results were blinded to the investigators throughout the study period. At position 389 of the β-1 adrenergic receptor gene (ADRB1), the observed minor Gly allele frequency (Gly389Arg + Gly389Gly) was 0.21, and no deviation from Hardy-Weinberg equilibrium was observed in the genotypic distribution of Arg389Gly (p = 0.75). Heart rate was reduced from 80.8 ± 14.3 to 70.0 ± 15.0 beats per minute (p < 0.0001). There was no significant difference in final heart rate across genotypes. However, the Arg389Arg genotype group required significantly more bisoprolol compared to the Gly389X (Gly389Arg + Gly389Gly) group (5.26 ± 2.62 mg vs. 3.96 ± 2.05 mg, p = 0.022). There were no significant differences in LVEF changes or remodeling between two groups. Also, changes in exercise capacity and brain natriuretic peptide level were not significant. However, interestingly, there was a two-fold higher rate of readmission (21.2% vs. 10.0%, p = 0.162) and one CHF-related death in the Arg389Arg group. Conclusions: The ADRB1 Gly389X genotype showed greater response to bisoprolol than the Arg389Arg genotype, suggesting the potential of individually tailoring β-blocker therapy according to genotype.
참고문헌 (39)
- Rienstra M, "Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis", JACC Heart Fail, 1, pp.21~28 (2013)
- Lee SE, "A multicentre cohort study of acute heart failure syndromes in Korea: rationale, design, and interim observations of the Korean Acute Heart Failure (KorAHF) registry", Eur J Heart Fail, 16, pp.700~708 (2014)
- 윤종찬, "Trends in Hospitalized Acute Myocardial Infarction Patients with Heart Failure in Korea at 1998 and 2008", Journal of Korean Medical Science, 29(4), pp.544~549 (2014), 대한의학회
- Small KM, "Synergistic polymorphisms of beta1-and alpha2C-adrenergic receptors and the risk of congestive heart failure", N Engl J Med, 347, pp.1135~1142 (2002)
- Borjesson M, "A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure", Eur Heart J, 21, pp.1853~1858 (2000)
- Forleo C, "Association of beta-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy", Am J Med, 117, pp.451~458 (2004)
- Cresci S, "Clinical and genetic modifiers of long-term survival in heart failure", J Am Coll Cardiol, 54, pp.432~444 (2009)
- Cappola TP, "Clinical considerations of heritable factors in common heart failure", Circ Cardiovasc Genet, 4, pp.701~709 (2011)
- Filigheddu F, "Genetic prediction of heart failure incidence, prognosis and beta-blocker response", Mol Diagn Ther, 17, pp.205~219 (2013)
- Liggett SB, "A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure", Proc Natl Acad Sci U S A, 103, pp.11288~11293 (2006)
- Liggett SB, "Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level", Circulation, 101, pp.1707~1714 (2000)
- Bruck H, "The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity", J Am Coll Cardiol, 46, pp.2111~2115 (2005)
- Rochais F, "Real-time optical recording of beta1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol", J Clin Invest, 117, pp.229~235 (2007)
- Fiuzat M, "Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTION DNA substudy", Eur J Heart Fail, 15, pp.258~266 (2013)
- Small KM, "Pharmacology and physiology of human adrenergic receptor polymorphisms", Annu Rev Pharmacol Toxicol, 43, pp.381~411 (2003)
- Shin J, "Pharmacogenetics of beta-blockers", Pharmacotherapy, 27, pp.874~887 (2007)
- Metra M, "Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure", Cardiovasc Drugs Ther, 24, pp.49~60 (2010)
- Biolo A, "Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy", Am J Cardiol, 102, pp.726~732 (2008)
- Mahesh Kumar KN, "Genetic polymorphisms of beta1 adrenergic receptor and their influence on the cardiovascular responses to metoprolol in a South Indian population", J Cardiovasc Pharmacol, 52, pp.459~466 (2008)
- Wood AJ, "Ethnic differences in drug disposition and responsiveness", Clin Pharmacokinet, 20, pp.350~373 (1991)
- 이해영, "Effects of intensive versus mild lipid lowering by statins in patients with ischemic congestive heart failure: Korean Pitavastatin Heart Failure (SAPHIRE) study", The Korean Journal of Internal Medicine, 29(6), pp.754~763 (2014), 대한내과학회[DOI]
- Muszkat M, "Interethnic differences in drug response:the contribution of genetic variability in beta adrenergic receptor and cytochrome P4502C9", Clin Pharmacol Ther, 82, pp.215~218 (2007)
- Ogimoto A, "Impact of synergistic polymorphisms in adrenergic receptor-related genes and cardiovascular events in patients with dilated cardiomyopathy", Circ J, 76, pp.2003~2008 (2012)
- Brodde OE, "Beta-1 and beta-2 adrenoceptor polymorphisms:functional importance, impact on cardiovascular diseases and drug responses", Pharmacol Ther, 117, pp.1~29 (2008)
- Azuma J, "Chronic heart failure: beta-blockers and pharmacogenetics", Eur J Clin Pharmacol, 65, pp.3~17 (2009)
- Yogev D, "Effects of sex and the common ADRB1 389 genetic polymorphism on the hemodynamic response to dobutamine", Pharmacogenet Genomics, 25, pp.555~563 (2015)
- Cullington D, "Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target?", Eur J Heart Fail, 14, pp.737~747 (2012)
- Greene SJ, "The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial", JACC Heart Fail, 1, pp.488~496 (2013)
- Biolo A, "Impact of beta-2 Thr164Ile and combined beta-adrenergic receptor polymorphisms on prognosis in a cohort of heart failure outpatients", Braz J Med Biol Res, 43, pp.565~571 (2010)
- White HL, "An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study", Eur J Heart Fail, 5, pp.463~468 (2003)
- Wagoner LE, "Polymorphisms of the beta1-adrenergic receptor predict exercise capacity in heart failure", Am Heart J, 144, pp.840~846 (2002)
- Terra SG, "Beta-adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release", extended release in heart failure, 2005, pp.77, 127~137
- Chen L, "Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol", Pharmacogenet Genomics, 17, pp.941~949 (2007)
- Liu WN, "beta1 adrenergic receptor polymorphisms and heart failure: a meta-analysis on susceptibility, response to beta-blocker therapy and prognosis", PLoS One, 7, pp.e37659~ (2012)
- Liu J, "beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension", Clin Pharmacol Ther, 80, pp.23~32 (2006)
- Terra SG, "Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy", Pharmacogenet Genomics, 15, pp.227~234 (2005)
- Petersen M, "Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients", Br J Clin Pharmacol, 71, pp.556~565 (2011)
- O’Connor CM, "Combinatorial pharmacogenetic interactions of bucindolol and beta1, alpha2C adrenergic receptor polymorphisms", PLoS One, 7, pp.e44324~ (2012)
- Mesangeau D, "Early detection of cardiovascular autonomic neuropathy in diabetic pigs using blood pressure and heart rate variability", Cardiovasc Res, 45, pp.889~899 (2000)